Are medical Marijuana users different from recreational users? the view from primary care

American Journal on Addictions

Volumn 24, Issue 7, 2015, Pages 599-606

  Roy Byrne, Peter ^a   Maynard, Charles ^b   Bumgardner, Kristin ^a   Krupski, Antoinette ^a   Dunn, Chris ^a   West, Imara I ^a   Donovan, Dennis ^a   Atkins, David C ^a   Ries, Richard ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; MEDICAL CANNABIS; RECREATIONAL DRUG;

ADULT; ARTICLE; CANNABIS USE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN EXPERIMENT; MOTIVATIONAL INTERVIEWING; NORMAL HUMAN; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SELF REPORT; SUBSTANCE USE; COMPARATIVE STUDY; HEALTH STATUS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PSYCHOLOGY; RECREATION; STATISTICS AND NUMERICAL DATA;

ADULT; CANNABIS; DRUG USERS; FEMALE; HEALTH STATUS; HUMANS; MALE; MEDICAL MARIJUANA; MIDDLE AGED; PRIMARY HEALTH CARE; RECREATION;

EID: 84942516008     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12270     Document Type: Article

References (28)

1. Aggarwal SK,. Cannabinergic pain medicine: A concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013; 29: 162-171.
2. Lynch ME, Campbell F,. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011; 72: 735-744.
3. Borgelt LM, Franson KL, Nussbaum AM, et al., The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33: 195-209.
4. Wilkinson ST, D'Souza DC,. Problems with the medicalization of marijuana. JAMA. 2014; 311: 2377-2378.
5. Volkow ND, Baler RD, Compton WM, et al., Adverse health effects of marijuana use. N Engl J Med. 2014; 370: 2219-2227.
6. Gilman JM, Kuster JK, Lee S, et al., Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci. 2014; 34: 5529-5538.
7. Filbey FM, Aslan S, Calhoun VD, et al., Long-term effects of marijuana use on the brain. Proc Natl Acad Sci USA. 2014; 111: 16913-16918.
8. Mojarrad M, Samet JH, Cheng DM, et al., Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: A prospective cohort study. Drug Alcohol Depend. 2014; 142: 91-97.
9. Asbridge M, Hayden JA, Cartwright JL,. Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. BMJ. 2012; 344: e536.
10. Li MC, Brady JE, DiMaggio CJ, et al., Marijuana use and motor vehicle crashes. Epidemiol Rev. 2012; 34: 65-72.
11. Furler MD, Einarson TR, Millson M, et al., Medicinal and recreational marijuana use by patients infected with HIV. Aids Patient Care STDS. 2004; 18: 215-228.
12. Ogborne AC, Smart RG, Weber T, et al., Who is using cannabis as a medicine and why: An exploratory study. J Psychoactive Drugs. 2000; 32: 435-443.
13. Ware MA, Adams H, Guy GW,. The medicinal use of cannabis in the UK: Results of a nationwide survey. Int J Clin Pract. 2005; 59: 291-295.
14. Reinarman C, Nunberg H, Lanthier F, et al., Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011; 43: 128-135.
15. Harris D, Jones RT, Shank R, et al., Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. J Addict Dis. 2000; 19: 89-103.
16. Ogborne AC, Smart RG, Adlaf EM,. Self-reported medical use of marijuana: A survey of the general population. CMAJ. 2000; 162: 1685-1686.
17. Krupski A, Joesch JM, Dunn C, et al., Testing the effects of brief intervention in primary care for problem drug use in a randomized controlled trial: Rationale, design, and methods. Addict Sci Clin Pract. 2012; 7: 27.
18. Smith PC, Schmidt SM, Allensworth-Davies D, et al., A single-question screening test for drug use in primary care. Arch Intern Med. 2010; 170: 1155-1160.
19. Yudko E, Lozhkina O, Fouts A,. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007; 32: 189-198.
20. Cacciola JS, Alterman AI, McLellan AT, et al., Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend. 2007; 87: 297-302.
21. The EuroQol Group,. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy Educ. 1990; 16: 199-208.
22. Darke S, Hall W, Heather N, et al., The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS. 1991; 5: 181-185.
23. Kronick R, Gilmer T, Dreyfus T, et al., Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev. 2000; 21: 29-64.
24. Pedersen W, Sandberg S,. The medicalization of revolt: A sociological analysis of medical cannabis users. Sociol Health Illn. 2013; 35: 17-32.
25. Lembke A,. Time to abandon the self-medication hypothesis in patients with psychiatric disorders. Am J Drug Alcohol Abuse. 2012; 38: 524-529.
26. Bachhuber MA, Saloner B, Cunningham CO, et al., Medical cannabis laws and opioid analgesic overdose: Mortality in the United States, 1999-2010. JAMA Intern Med 2014; 174: 1668-1673.
27. Washington State Agency Medical Directors Group., Interagency guideline on opioid dosing for chronic non-cancer pain. 2010.
28. Wilsey B, Atkinson JH, Marcotte TD, et al., The medicinal cannabis treatment agreement: Providing information to chronic pain patients via a written document. Clin J Pain. 2014, Nov 3; epub ahead of print.